Oracle Target Cut: AI Costs Loom Large 01/23/26
/
RSS Feed
Oracle Target Cut: AI Costs Loom Large 01/23/26
Key Stories:
- Oracle, the enterprise software and cloud services giant, is facing concerns over its artificial intelligence infrastructure spending. A Morgan Stanley analyst has cut their price target on Oracle shares to $213 from an earlier $320, while maintaining an Equal-Weight rating. This significant revision comes as the analyst believes the costs associated with building out AI capabilities are being underestimated. The new $213 price target implies about a 20% upside from Oracle’s recent closing price of $178.18, a sharp contrast to the previous target which suggested an 80% gain. This highlights how the race for AI dominance might impact profitability and future valuations for even the biggest tech players. Read more
- Shifting gears to portfolio construction, many investors, especially those nearing or in retirement, grapple with balancing growth potential and income stability. Consider the case of a 75-year-old investor whose portfolio is split between the high-growth tech powerhouse NVIDIA, the leading artificial intelligence chip maker, and several defensive dividend payers. These income-generating stalwarts include Johnson & Johnson, the global healthcare and pharmaceutical giant, telecommunications firm Verizon, consumer goods behemoth Procter & Gamble, and beverage giant Coca-Cola. The core question for such an investor isn’t necessarily the quality of these individual holdings, but rather whether to simplify their strategy to better suit retirement goals, a common dilemma for long-term holders of both disruptive tech and stable dividend stocks. Read more
- Speaking of one of those defensive dividend payers, Johnson & Johnson, the global healthcare and pharmaceutical giant, recently received a positive outlook from analysts. TD Cowen has raised its price target on Johnson & Johnson shares to $250, up from $222, reiterating a Buy rating on the stock. This upgrade follows strong fourth-quarter results, where the company reported $24.6 billion in revenue, handily beating consensus estimates. Analysts also noted that Johnson & Johnson’s initial 2026 guidance is likely to boost Wall Street’s revenue and earnings per share forecasts. The firm anticipates continued momentum in J&J’s pharmaceutical and medical devices franchises from the second half of 2025 and well into 2026, signaling robust future performance. Read more
Keywords: AI costs, Coca-Cola, JNJ, Johnson & Johnson, KO, Morgan Stanley, NVDA, NVIDIA, ORCL, Oracle, PG, Procter & Gamble, Q4 earnings, TD Cowen, VZ, Verizon, analyst rating, cloud computing, dividend stocks, enterprise software, growth stocks, healthcare, medical devices, pharmaceuticals, portfolio diversification, price target, retirement investing, revenue